Dr Herrera explains why N+AVD is a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin lymphoma.
Back
Nivolumab Plus AVD Prolongs PFS in Advanced-Stage Hodgkin Lymphoma
Alex F. Herrera, MD, discusses key data from the phase 3 S1826 trial (NCT03907488) evaluating nivolumab plus AVD vs brentuximab vedotin plus AVD in adolescent and adult patients with stage III or IV advanced-stage classic Hodgkin lymphoma.
Nivolumab Plus AVD Prolongs PFS in Advanced-Stage Hodgkin Lymphoma
Episodes
All
All
Alex F. Herrera, MD, discusses long-term data from nivolumab plus AVD in advanced-stage Hodgkin lymphoma.
Alex Herrera, MD, discusses safety and efficacy outcomes with nivolumab plus AVD vs brentuximab vedotin plus AVD in advanced classic Hodgkin lymphoma.
Nivolumab plus AVD prolonged median PFS vs brentuximab vedotin plus AVD in patients with stage III or IV advanced-stage classic Hodgkin lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
CARiBOU Regimen Drives Complete Metabolic Responses in First-Line Mantle Cell Lymphoma
4
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
5